How Mosunetuzumab works

Mosunetuzumab is an innovative drug whose main mechanism of action involves the field of immunotherapy. This drug is designed and used to help patients' immune systems fight malignant B cells more effectively, and has shown potential in the treatment of malignant tumors such as diffuse large B cell lymphoma (DLBCL).

The mechanism of action of motuzumab can be summarized as the following key steps:

1.Bispecific antibody structure: Motuzumab has a unique antibody structure that can target two different proteins at the same time, namely CD3 and CD20. CD3is present on the surface of T cells, while CD20 is mainly present on the surface of B cells, including malignant B cells.

2.Connecting T cells and B cells: by simultaneously binding CD3 and CD20, motuzumab guides the patient's T cells to the vicinity of the cancer B cells.

3. Activation of T cells: Once T cells are exposed to CD20 positive Of malignant B cells, motuzumab prompts T cells to release toxic substances, such as perforin and cytotoxic enzymes, to directly attack cancer cells.

4.Immune cell enhancement: In addition to activatingT cells, motuzumab can also activate natural killer cells (NK cells) and other immune cells, enhancing the immune system's attack on malignant B cells.

5.Immune memory: The drug also has the potential to enhance the immune system's ability to recognize and attack future cancer cells, as it helps T cells form immune memory so that the body can better fight the recurrence of cancer cells.

In general, the mechanism of action of motuzumab is by connecting T cells and B cells in the immune system, thereby activating immune cells so that they can more effectively recognize, locate and destroy malignant B cells. The design of this bispecific antibody makes it have great potential in cancer treatment, especially in the treatment of refractory or relapsed DLBCL and other diseases.